UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 246

Sortiert nach

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2022-01, Vol.23 (1), p.91-103

2022

Volltextzugriff (PDF)

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

The New England journal of medicine, 2012-07, Vol.367 (2), p.135-145

2012

Volltextzugriff (PDF)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

PloS one, 2016-06, Vol.11 (6), p.e0158156

2016

Volltextzugriff (PDF)

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation

Scientific reports, 2021-02, Vol.11 (1), p.3230-3230, Article 3230

2021

Volltextzugriff (PDF)

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Nature communications, 2017-12, Vol.8 (1), p.2125-14, Article 2125

2017

Volltextzugriff (PDF)

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

Journal of clinical oncology, 2021-06, Vol.39 (17), p.1878-1887

2021

Volltextzugriff (PDF)

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Annals of hematology, 2021-07, Vol.100 (7), p.1863-1870

2021

Volltextzugriff (PDF)

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis

Blood, 2017-02, Vol.129 (7), p.906-916

2017

Volltextzugriff (PDF)

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

Frontiers in oncology, 2021-05, Vol.11 (16), p.664688-664688

2021

Volltextzugriff (PDF)

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation

The Journal of immunology (1950), 2016-02, Vol.196 (3), p.1070-1080

2016

Volltextzugriff (PDF)

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Blood reviews, 2021-01, Vol.45, p.100695-100695, Article 100695

2021

Volltextzugriff (PDF)

Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose

Transfusion and apheresis science, 2021-02, Vol.60 (1), p.103081-103081, Article 103081

Reshef, Ran

2021

Volltextzugriff (PDF)

Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation

Clinics in chest medicine, 2017-12, Vol.38 (4), p.771-783

2017

Volltextzugriff (PDF)

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Biology of blood and marrow transplantation, 2016-01, Vol.22 (1), p.4-10

2016

Volltextzugriff (PDF)

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

The Journal of heart and lung transplantation, 2012-03, Vol.31 (3), p.296-304

2012

Volltextzugriff (PDF)

682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A774-A774

2023

Volltextzugriff (PDF)

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN‐LABEL GLOBAL PHASE3 STUDY OF TAB‐CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

HemaSphere, 2023-08, Vol.7 (S3), p.e0490265-n/a

2023

Volltextzugriff (PDF)

TGM4: an immunogenic prostate-restricted antigen

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e001649

2021

Volltextzugriff (PDF)

P1107: ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

HemaSphere, 2023-08, Vol.7 (S3), p.e6350662-n/a

2023

Volltextzugriff (PDF)

P871: IDECABTAGENE VICLEUCEL (IDE‐CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA‐2 COHORT 2C

HemaSphere, 2023-08, Vol.7 (S3), p.e90596a3-n/a

2023

Volltextzugriff (PDF)

Precision in donor selection: identifying ideal stem-cell donors through their T-cells

Experimental hematology, 2016-11, Vol.44 (11), p.1020-1023

2016

Volltextzugriff (PDF)

168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A101-A101

2020

Volltextzugriff (PDF)

Improved accuracy of acute graft-versus-host disease staging among multiple centers

Best practice & research. Clinical haematology, 2014-09, Vol.27 (3), p.283-287

2014

Volltextzugriff (PDF)

Posttransplant Lymphoproliferative Disorder Following Kidney Transplant

American journal of kidney diseases, 2010-01, Vol.55 (1), p.168-180

2010

Volltextzugriff (PDF)

1 – 25 von 246

Suche als RSS-Feed

Aktive Filter

KollektionEbook Central Perpetual and DDA

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(236)

Sprache

Englisch
(246)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(89)
Life Sciences & Biomedicine
(84)
Humans
(64)
Hematology
(54)
Transplantation
(39)
Male
(36)
Female
(34)
Aged
(29)
Middle Aged
(29)
Adult
(28)
Hematopoietic Stem Cell Transplantation - Adverse Effects
(23)
Immunology
(23)
Transplantation, Homologous
(20)
Hematology, Oncology And Palliative Medicine
(19)
Graft Vs Host Disease - Prevention & Control
(18)
Hematopoietic Stem Cell Transplantation - Methods
(17)
Young Adult
(17)
Oncology
(16)
Treatment Outcome
(14)
Animals
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation

Ezh2 phosphorylation state determines its capacity to maintain CD8 + T memory precursors for antitumor immunity

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

Revving the CAR – Combination strategies to enhance CAR T cell effectiveness

Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose

Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium

Post-transplant lymphoproliferative disorder after lung transplantation: A review of 35 cases

682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation

P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN‐LABEL GLOBAL PHASE3 STUDY OF TAB‐CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

TGM4: an immunogenic prostate-restricted antigen

P1107: ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

P871: IDECABTAGENE VICLEUCEL (IDE‐CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA‐2 COHORT 2C

Precision in donor selection: identifying ideal stem-cell donors through their T-cells

168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target

Improved accuracy of acute graft-versus-host disease staging among multiple centers

Posttransplant Lymphoproliferative Disorder Following Kidney Transplant

Aktive Filter

Suchergebnisse filtern